15 Mar 2021

Former Head Of Business Development, Alliances And Solutions At Zoetis, Michelle Haven, Joins Animol Discovery Board Of Directors


Animol Discovery, a biotechnology company delivering break-through novel small molecule drugs for the animal health industry based on its unique technology platform, announced today that Michelle Haven has joined the company’s Board of Directors.

Dr. Haven, currently Senior Adviser and Venture Partner at Anterra Capital, comes to Animol with more than 25 years of experience in the animal health industry, most recently as Senior Vice President for Business Development, Alliances and Solutions at Zoetis, Inc. Prior to that, she led global pharmaceutical and biological research at Pfizer Animal Health for several years and contributed to the development of multiple successful products. Dr. Haven holds a DVM from the University of Illinois at Urbana-Champaign, is board certified in the American College of Veterinary Surgeons and holds a Ph.D. in Physiology from North Carolina State University.

“I am excited to join the Board of Directors of Animol Discovery and look forward to working with the board and the company’s management team to advance Animol’s drug discovery program and to assist the company with its plan to further develop their unique discovery platform," said Dr. Haven. “I am convinced that Animol has a truly outstanding platform that will provide unprecedented capabilities to screen, discover and develop a large number of innovative small molecule drugs for veterinary medicine”.

“We are delighted to welcome Dr. Haven to our Board of Directors”, said Andrew Calabrese co-founder of Animol Discovery. “Her extensive experience in Animal Health Drug Discovery and Development as well as in building strong external partnerships around innovation will strengthen our Board of Directors”.

About Animol Discovery
Animol is a drug discovery company that leverages leading-edge advancements from biotechnology to build a proprietary pipeline of highly innovative pharmaceuticals for veterinary patients. Animol’s unique platform consists of advanced machine learning in combination with DNA-encoded chemical library screens. The Animol team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts and scientists. Animol Discovery is a private company headquartered in Boston, Massachusetts.


01 Jan 2020

Animol Discovery Announces $6 Million Seed Financing From Anterra Capital To Build High Value Pipeline Of Break-through Small Molecules For Animal Health


Animol Discovery, Inc. today announced receiving $6 million in seed financing from Anterra Capital to identify and develop its own pipeline of break-through proprietary veterinary small molecules. Based on a unique platform of DNA-encoded libraries (DEL) in combination with advanced machine learning/AI, Animol will deliver unprecedented number of novel compounds in the areas of antiparasitics and therapeutics. Over the coming year Animol Discovery will identify and subsequently develop medicines for companion animals and livestock, either by itself or in cooperation with Animal Health companies.

Andrew Calabrese, Animol Discovery’s scientific co-founder, highlighted the outstanding potential of Animol’s platform to identify tailor-made pharmaceuticals for the Animal Health market: “The powerful combination of DEL and machine learning signifies a huge step forward in applying artificial intelligence to find better drugs. Being able to screen drug targets at much reduced time and cost allows us to address unmet medical needs in a broad range of indication areas.”

Animol Discovery is one of several startup companies incubated by Amsterdam and Boston based Anterra Capital. “With Animol Discovery we continue our successful strategy of leveraging cutting-edge technology originally developed for human health to innovate and create value in underserved industries such as Animal Health”, said Philip Austin, Managing Partner at Anterra Capital.

About Animol Discovery
Animol is a drug discovery company that leverages leading-edge advancements from biotechnology to build a proprietary pipeline of highly innovative pharmaceuticals for veterinary patients. The Animol team of highly experienced R&D leaders from both human biotech and animal health is supported by best-in-class biotechnology partners and an extensive network of industry experts and scientists. Animol Discovery is a private company headquartered in Boston, Massachusetts.

About Anterra
Anterra Capital is a specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture and animal health. Anterra is a provider of patient strategic capital as part of a global network of growth capital funds supported by financial services multinationals Rabobank and Fidelity. For more information, see www.anterracapital.com.